- Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) — Active Not Recruiting • Phase III • NCT05925803.
- Anifrolumab injection versus placebo tested in early systemic sclerosis patients to assess effectiveness and safety.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom. Conditions: Systemic Sclerosis, Scleroderma Interventions: Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label) Lead Sponsor: AstraZeneca Planned Enrollment: 314 participants